Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Large Growth in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totaling 134,469 shares, an increase of 27,740.4% from the April 30th total of 483 shares. Approximately 1.2% of the company’s shares are short sold. Based on an average trading volume of 525,489 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of Hong Kong Pharma Digital Technology

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new position in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology as of its most recent filing with the Securities and Exchange Commission (SEC).

Hong Kong Pharma Digital Technology Stock Up 0.4%

Shares of Hong Kong Pharma Digital Technology stock traded up $0.00 during trading on Wednesday, hitting $0.54. The stock had a trading volume of 19,192 shares, compared to its average volume of 98,047. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.73 and a current ratio of 2.93. The stock has a 50 day simple moving average of $0.61 and a 200 day simple moving average of $0.75. Hong Kong Pharma Digital Technology has a 1 year low of $0.37 and a 1 year high of $2.76.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.01 EPS for the quarter. The company had revenue of $3.57 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.